The standard timeline given for developing a new drug from bench to bedside is 10+ years, a figure well-known to the scientific community. But less than one year after COVID-19 was declared a pandemic, multiple vaccinations were approved for use across the globe. At the time of writing, the vaccination programme in the UK, like many countries, is racing through our adult population with talks of booster jabs being ready for use by the autumn.
In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma.
Posted by Rebecca Dargue
Health Science Content Writer
